T2 Biosystems Inc
3T2
Company Profile
Business description
T2 Biosystems Inc is a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes. It is dedicated to improving patient care and reducing the cost of care by helping clinicians effectively treat patients faster than ever before. The company’s products include the T2Dx Instrument, the T2Bacteria Panel, the T2Candida Panel, the T2Resistance Panel, and the T2Biothreat Panel, and are powered by the proprietary T2 Magnetic Resonance technology.
Contact
101 Hartwell Avenue
LexingtonMA02421
USAT: +1 781 761-4646
Sector
Healthcare
Stock type
Defensive
Industry
Diagnostics & Research
Fiscal Year End
31 December 2024
Employees
113
Stocks News & Analysis
stocks
Why we’ve downgraded this ASX software player
Morningstar lowers our fair value estimate for Megaport by 16% after mispricing leads to a downgrade in capital allocation rating.
stocks
The market hates this compelling ASX income play
Santos continues to trade at a valuation that implies no growth in the years ahead. Our analyst Mark Taylor thinks that is misguided.
stocks
Lessons from the top performing ASX share
Chasing performance can lead to poor results but investors can still learn from top performers.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,754.70 | 49.70 | 0.57% |
| CAC 40 | 7,255.42 | 18.53 | 0.26% |
| DAX 40 | 20,016.75 | 83.13 | 0.42% |
| Dow JONES (US) | 44,745.33 | 36.67 | -0.08% |
| FTSE 100 | 8,359.41 | 46.52 | 0.56% |
| HKSE | 19,746.32 | 196.03 | 1.00% |
| NASDAQ | 19,457.98 | 54.03 | 0.28% |
| Nikkei 225 | 39,248.86 | 735.84 | 1.91% |
| NZX 50 Index | 13,093.18 | 21.50 | -0.16% |
| S&P 500 | 6,050.76 | 3.61 | 0.06% |
| S&P/ASX 200 | 8,495.20 | 47.30 | 0.56% |
| SSE Composite Index | 3,378.81 | 14.82 | 0.44% |